MEDIROM Announces Receipt of Nasdaq Delisting Notice, Filing of Annual Report and Submission of Hearing Request
Key Highlights
- ➤MEDIROM filed its overdue 2025 Form 20-F with the SEC on November 18, 2026
- ➤Nasdaq delisting determination appealed; hearing request automatically stays suspension for 15 days
- ➤MEDIROM requested an extended trading-suspension stay pending the Nasdaq hearing process
- ➤Nasdaq minimum bid-price deficiency remains unresolved; compliance deadline is April 5, 2027
TOKYO, Nov. 18, 2026 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq: MRM) (the “Company”) today announced that on November 13, 2026, it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) because the Company had not filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the “Annual Report”) within the extension period previously granted by Nasdaq and therefore had not regained compliance with Nasdaq Listing Rule 5250(c)(1).
As previously disclosed, Nasdaq notified the Company on May 26, 2026, that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) because it had not timely filed the Annual Report. Nasdaq subsequently granted the Company an extension to regain compliance. The Company did not file the Annual Report within that extension period. The Notice stated that unless the Company requests an appeal of the delisting determination, trading of the Company’s American Depositary Shares will be subject to suspension and delisting from Nasdaq at the opening of business on November 24, 2026.
Get started
Create a free account to read the full story.
